Advocates are urging the Department of Justice to cease defending Biden-era regulations that allow mifepristone to be sent through the mail. The push seeks to restore in-person medical requirements to prevent domestic abuse and serious health complications.
Rosalie Markezich’s experience in Louisiana highlights the risk of coercion
The current legal battle over mail-order abortion drugs stems from a regulatory legacy established during the COVID-19 pandemic. This policy allows for the delivery of mifepristone without the traditional face-to-face medical consultations that once served as a primary safeguard. As reported in recent appeals, this lack of oversight has created vulnerabilities that state laws struggle to address.
In Louisiana, the case of Rosalie Markezich serves as a primary example of how these regulations can be exploited. Markezich alleges she was coerced by her then-boyfriend into consuming abortion medication that had been ordered online from another state. Because the drugs were delivered to a remote location without a doctor present to verify consent, Markezich maintains that she was unable to reverse the process, a situation she believes would have been avoided with in-person medical gatekeepers.
The 75% emergency room statistic from the Charlotte Lozier Institute
Beyond the issue of coercion,medical professionals and advocates are raising alarms regarding the physiological risks of unsupervised drug use. According to research provided by the Charlotte Lozier Institute, approximately 75 percent of emergency room visits occurring within 30 days of using abortion drugs are classified as severe or critical. This data suggests that the absence of clinical oversight may lead to significant medical crises.
The real-world consequences of these statistics are seen in patients like Shanyce Thomas, who was placed in a medically induced coma and lost her fertility, and Haile McAnally, who required a life-saving blood transfusion after being found unconscious. Furthermore, evidence suggests that as many as 11 percent of women may experience serious adverse side effects, including sepsis, systemic infection, or severe hemorrhage, when using mifepristone without direct medical supervision.
Non-consensual medication cases in Ohio and Texas
The ease of procuring medications online has also been linked to a disturbing trend of domestic violence where abusers use abortion drugs to harm women without their knowledge.. This form of violence bypasses the traditional medical safeguards designed to ensure a patient's autonomy and health.
Specific instances of this trend include Jona Affholder in Ohio, who lost an unborn child after being force-fed medication by a partner, and Catherine Herring in Texas, who reportedly faced seven separate attempts by her former husband to end her pregnancy through non-consensual drug administration. These cases underscore the argument that mail-order access removes the "medical gatekeepers" who typically verify a patient's intent and physical well-being.
The September 9 deadline and the Heidi Overton FDA study
The Department of Justice now faces pressure to settle ongoing legal cases before a critical September 9 deadline. Proponents of restoring in-perosn requirements argue that such a move would uphold state sovereignty and could potetially prevent the loss of approximately 15,000 babies every month in states where current protections are bypassed.
While the immediate administrative response is being debated, the scientific community is still gathering data. An FDA study led by Heidi Overton is expected to eventually provide long-term safety data regarding mifepristone. However,critics of the current policy argue that the administration cannot wait for long-term studies while women continue to face immediate risks of medical complications and domestic abuse through mail-order access.
Comments 0